|
Objective: To compare paclitaxel micro blind hole drug-loaded stent with rapamycin-eluting stents in acute ST-segment elevation myocardial infarction (ST-elevation myocardial infarction, STEMI) direct percutaneous coronary intervention treatment (percutaneous coronary intervention, PCI) in the application of safety and efficacy. Methods: consecutive October 2008 to April 2010 for treatment at Tianjin Nankai Hospital Cardiology diagnosed as STEMI, a direct PCI 105 patients were randomly divided into two groups, paclitaxel group placed paclitaxel micro blind hole drug-loaded stent, A total of 50 cases, rapamycin-eluting stent group home Rulei Pa neomycin, a total of 55 cases. Records of patients enrolled in the clinical data, coronary angiography, surgery information, such as telephone, outpatient and inpatient follow-up of the two groups of patients, 6-month review of coronary angiography. Comparing two groups of patients during hospitalization, after 30 days, after 6 months, 1 year after stent thrombosis (stent thrombosis, ST), the incidence of adverse cardiovascular events (major adverse cardiac events, MACE), 6 month angiographic follow-up rate of restenosis, late lumen loss, missing index. SPSS17.0 statistical software, measurement data to x ± s two mean compared using independent sample test u test count data with x2 test or exact test. P lt; 0.05 is a statistically significant difference. Results: no significant difference between the two groups of patients enrolled in the clinical data, coronary angiography, surgery information. The two sets of data are comparable. Two groups of 71.4% (75/105) of cases of coronary angiography, which the paclitaxel group of 70% (35/50), rapamycin group, 72.7% (40/55), the follow-up rate of target lesion paclitaxel group 76.8% ( 53/69), rapamycin group, 77.8% (56/72). Compared with the rapamycin group, the the paclitaxel group of late diameter loss, percent diameter stenosis, lost the index no significant reduction (P gt; 0.05). Paclitaxel coronary angiography segment restenosis rate was 14.3% (5/35), rapamycin group segment restenosis rate of 10.0% (4/40) (14.3% vs 10.0%, P = 0.571). The paclitaxel group hospitalization during follow-up 30 days, 6 months, 12 months were not found in acute, subacute and late thrombosis. Rapamycin group found cases of subacute thrombosis, no acute and late thrombosis. The incidence of thrombosis of the two groups showed no significant difference. Two sets of cumulative MACE rate during hospitalization (0 vs. 1.8%, P gt; 0.05) after 30 days (0 to 1.8%, P gt; 0.05) after 6 months (6.0% vs 5.5%, P gt; 0.05), after 12 months (20.8% vs 10.9%, P gt; 0.05) differences were not statistically significant. Conclusion: The drug-loaded stent paclitaxel micro blind hole with rapamycin-eluting stents in STEMI patients directly to PCI application of safety and efficacy.
|